198 related articles for article (PubMed ID: 33621602)
1. Effect of oral vancomycin dose on outcomes in patients with Clostridioides difficile infection.
O'Donnell JN; Novak GM; Bratek BR; Singh G; Duru OO; Mitchell CL; Roddy KM; Bidell MR
Int J Antimicrob Agents; 2021 Apr; 57(4):106311. PubMed ID: 33621602
[TBL] [Abstract][Full Text] [Related]
2. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
3. Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
Wang Y; Schluger A; Li J; Gomez-Simmonds A; Salmasian H; Freedberg DE
Clin Infect Dis; 2020 Dec; 71(9):2414-2420. PubMed ID: 31714955
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.
Stevens VW; Nelson RE; Schwab-Daugherty EM; Khader K; Jones MM; Brown KA; Greene T; Croft LD; Neuhauser M; Glassman P; Goetz MB; Samore MH; Rubin MA
JAMA Intern Med; 2017 Apr; 177(4):546-553. PubMed ID: 28166328
[TBL] [Abstract][Full Text] [Related]
5. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
Gentry CA; Campbell DL; Williams RJ
Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
[TBL] [Abstract][Full Text] [Related]
6. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection.
Wenisch JM; Schmid D; Kuo HW; Allerberger F; Michl V; Tesik P; Tucek G; Laferl H; Wenisch C
Antimicrob Agents Chemother; 2012 Apr; 56(4):1974-8. PubMed ID: 22252830
[TBL] [Abstract][Full Text] [Related]
7. Impact of oral vancomycin treatment duration on rate of
Kwiatkowski D; Marsh K; Katz A; Papadopoulos J; So J; Major VJ; Sommer PM; Hochman S; Dubrovskaya Y; Arnouk S
Infect Control Hosp Epidemiol; 2024 Jun; 45(6):717-725. PubMed ID: 38288606
[TBL] [Abstract][Full Text] [Related]
8. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
9. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial.
Hota SS; Sales V; Tomlinson G; Salpeter MJ; McGeer A; Coburn B; Guttman DS; Low DE; Poutanen SM
Clin Infect Dis; 2017 Feb; 64(3):265-271. PubMed ID: 28011612
[TBL] [Abstract][Full Text] [Related]
10. Optimal vancomycin dose in the treatment of
Ereshefsky BJ; Alrahmany D; El Nekidy WS; Pontiggia L; Ghazi IM
J Chemother; 2021 May; 33(3):165-173. PubMed ID: 32715951
[No Abstract] [Full Text] [Related]
11. The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study.
Manea E; Sojo-Dorado J; Jipa RE; Benea SN; Rodríguez-Baño J; Hristea A
Clin Microbiol Infect; 2018 Feb; 24(2):180-184. PubMed ID: 28642147
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of LFF571 in a hamster model of Clostridium difficile infection.
Trzasko A; Leeds JA; Praestgaard J; Lamarche MJ; McKenney D
Antimicrob Agents Chemother; 2012 Aug; 56(8):4459-62. PubMed ID: 22644020
[TBL] [Abstract][Full Text] [Related]
13. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
[TBL] [Abstract][Full Text] [Related]
14. Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses.
Caroff DA; Menchaca JT; Zhang Z; Rhee C; Calderwood MS; Kubiak DW; Yokoe DS; Klompas M
Infect Control Hosp Epidemiol; 2019 Jun; 40(6):662-667. PubMed ID: 31030679
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe Clostridioides difficile Infection.
Vega AD; Heil EL; Blackman AL; Banoub M; Kristie Johnson J; Leekha S; Claeys KC
Pharmacotherapy; 2020 May; 40(5):398-407. PubMed ID: 32246501
[TBL] [Abstract][Full Text] [Related]
16. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs.
Le F; Arora V; Shah DN; Salazar M; Palmer HR; Garey KW
Pharmacotherapy; 2012 Feb; 32(2):129-34. PubMed ID: 22392421
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of early-targeted use of fidaxomicin versus oral vancomycin among hospitalized veterans' affairs patients with infections due to Clostridioides difficile.
Patel N; Lowry C; Morgenson D; Shah V; Stornelli N; Lodise TP
Pharmacotherapy; 2021 Feb; 41(2):212-219. PubMed ID: 33455007
[TBL] [Abstract][Full Text] [Related]
18. Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis.
Muhammad A; Simcha W; Rawish F; Sabih R; Albert E; Ali N
Curr Clin Pharmacol; 2020; 15(1):4-10. PubMed ID: 31376824
[TBL] [Abstract][Full Text] [Related]
19. Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci.
Stevens VW; Khader K; Echevarria K; Nelson RE; Zhang Y; Jones M; Timbrook TT; Samore MH; Rubin MA
Clin Infect Dis; 2020 Jul; 71(3):645-651. PubMed ID: 31504328
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.
Johnson SW; Brown SV; Priest DH
Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
